Eosinophilic Asthma Industry Anticipated to Expand at 17.1% CAGR During the Forecast Period

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Are The Forecasted Market Size Estimates For The Eosinophilic Asthma Market Between 2025 And 2029?

The eosinophilic asthma market size has seen rapid growth in recent years. It is forecast to expand from $2.69 billion in 2024 to $3.16 billion in 2025, achieving a compound annual growth rate (CAGR) of 17.4%. The historical period’s expansion can be ascribed to several factors, including an increase in pollution, lower immunity in the population, a rise in the prevalence of eosinophilic asthma, an increase in the prevalence of allergens and respiratory conditions, a rise in healthcare expenditure, and an uptick in R&D activities.

The eosinophilic asthma market is projected to experience substantial growth in the upcoming years. It is expected to expand to $5.95 billion by 2029, achieving a compound annual growth rate (CAGR) of 17.1%. This expansion during the forecast period can be attributed to the increasing incidence of respiratory conditions, enhanced awareness and improved diagnosis rates, broader therapeutic uses for monoclonal antibodies, increased investment in healthcare infrastructure, and the growing adoption of personalized medicine techniques. Significant trends anticipated in this period encompass the creation of targeted biologics, advancements in diagnostic instruments, individualized treatment strategies, improved drug delivery systems, the integration of digital health technologies, and an increase in clinical trials for innovative therapies.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=21184&type=smp

What Are The Drivers Pushing New Developments In The Eosinophilic Asthma Market?

The anticipated rise in smoking habits is expected to drive the expansion of the eosinophilic asthma market in the future. Smoking habits refer to consistent behaviors or patterns involving the consumption of tobacco products, such as how often, where, and for how long individuals smoke, often influenced by psychological, social, and environmental factors. This increase in smoking can be attributed to factors like heightened stress levels, strategic marketing by tobacco companies, insufficient understanding of health risks, and the social normalization of smoking in certain communities. Eosinophilic asthma treatment helps mitigate airway inflammation and enhance lung function, which can support smoking cessation by easing the respiratory issues that frequently motivate patients to continue smoking. As an illustration, in December 2023, the National Health Service, a UK-based government department, reported an estimated 408,700 hospital admissions attributed to smoking in 2022–23, an increase of 4.8% from 389,800 admissions in 2021–22. Consequently, the escalating smoking rates are a key driver for the eosinophilic asthma market.

What Are The Key Segments In The Eosinophilic Asthma Market?

The eosinophilic asthmamarket covered in this report is segmented –

1) By Disease: Severe Eoisnophilic Asthma; Mild To Moderate Eosinophilic Asthma

2) By Treatment: Biologics; Bronchodilators; Corticosteroids; Immunomodulators; Other Treatments

3) By End User: Hospitals; Clinics; Other End Users

Subsegments:

1) By Severe Eosinophilic Asthma: Refractory Eosinophilic Asthma; Late-Onset Eosinophilic Asthma

2) By Mild To Moderate Eosinophilic Asthma: Early-Onset Eosinophilic Asthma; Intermittent Eosinophilic Asthma

What Trends Are Expected To Drive The Eosinophilic Asthma Market?

Leading firms in the eosinophilic asthma sector are creating novel medications designed to target specific immunological pathways, lessen inflammation, and enhance patient results via tailored therapeutic approaches. Monoclonal antibodies are lab-engineered molecules capable of replicating the immune system’s defense against dangerous pathogens like viruses and bacteria, produced by merging an antibody-generating cell with a cancer cell to yield numerous identical antibodies. As an illustration, in August 2024, AstraZeneca plc, a biopharmaceutical company based in the UK, revealed the approval of Fasenra by China’s National Medical Products Association, a Chinese governmental body, for treating severe eosinophilic asthma. This medication is specifically prescribed for individuals suffering from severe eosinophilic asthma, a condition marked by elevated eosinophil counts, which often results in inflammation and intensified asthma symptoms. It functions as a monoclonal antibody that uniquely targets and reduces eosinophil levels. Fasenra boosts the immune system’s efficacy by attaching to the IL-5 receptor on eosinophils, thereby decreasing eosinophil concentrations in both blood and tissues. Its dosing schedule includes an initial loading phase, followed by subsequent maintenance doses. Typically, patients receive injections every four weeks for the initial three doses, and then every eight weeks subsequently.

Who Are The Top Performing Companies In The Eosinophilic Asthma Market In Recent Years?

Major companies operating in the eosinophilic asthma market are Roche Holding AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, Novartis AG, GSK plc, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Limited, Boehringer Ingelheim GmbH, Regeneron Pharmaceuticals Inc., Chiesi Farmaceutici S.p.A.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/eosinophilic-asthma-global-market-report

Which Global Regions Are Influencing The Competitive Landscape Of The Eosinophilic Asthma Market?

North America was the largest region in the eosinophilic asthma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the eosinophilic asthma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Eosinophilic Asthma Market Report:

https://www.thebusinessresearchcompany.com/customise?id=21184&type=smp

Browse Through More Reports Similar to the Global Eosinophilic Asthma Market 2025, By The Business Research Company

Anti Asthmatics And Copd Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/anti-asthmatics-and-copd-drugs-global-market-report

Asthma Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/asthma-drugs-global-market-report

Autoimmune Disease Diagnosis Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/autoimmune-disease-diagnosis-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795